{"title":"社论:艾滋病新药:现状如何?","authors":"Charles W Flexner, Angela Kashuba","doi":"10.1097/COH.0000000000000710","DOIUrl":null,"url":null,"abstract":"The WHO estimates that by the beginning of 2021, 27.5 million adults and children were receiving antiretroviral treatment [1]. Many of these individuals are taking a coformulated generic combination of dolutegravir with tenofovir disoproxil fumarate (TDF) and lamivudine (TLD), a daily oral combination that could be thought of as the ‘universal antiretroviral regimen [2]’. In the face of numbers like this, one could easily wonder if there is even a need for new treatments for HIV. Although it has been more than 3 years since this journal reviewed the topic of ‘New Drugs for HIV’, the Table of","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Editorial: New drugs for HIV: quo vadis?\",\"authors\":\"Charles W Flexner, Angela Kashuba\",\"doi\":\"10.1097/COH.0000000000000710\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The WHO estimates that by the beginning of 2021, 27.5 million adults and children were receiving antiretroviral treatment [1]. Many of these individuals are taking a coformulated generic combination of dolutegravir with tenofovir disoproxil fumarate (TDF) and lamivudine (TLD), a daily oral combination that could be thought of as the ‘universal antiretroviral regimen [2]’. In the face of numbers like this, one could easily wonder if there is even a need for new treatments for HIV. Although it has been more than 3 years since this journal reviewed the topic of ‘New Drugs for HIV’, the Table of\",\"PeriodicalId\":10949,\"journal\":{\"name\":\"Current Opinion in HIV and AIDS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in HIV and AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COH.0000000000000710\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in HIV and AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COH.0000000000000710","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
The WHO estimates that by the beginning of 2021, 27.5 million adults and children were receiving antiretroviral treatment [1]. Many of these individuals are taking a coformulated generic combination of dolutegravir with tenofovir disoproxil fumarate (TDF) and lamivudine (TLD), a daily oral combination that could be thought of as the ‘universal antiretroviral regimen [2]’. In the face of numbers like this, one could easily wonder if there is even a need for new treatments for HIV. Although it has been more than 3 years since this journal reviewed the topic of ‘New Drugs for HIV’, the Table of
期刊介绍：
Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in HIV and AIDS features hand-picked review articles from our team of expert editors. With six disciplines published across the year – including HIV and ageing, a HIV vaccine, and epidemiology – every issue also contains annotated reference detailing the merits of the most important papers.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
